Ozempic's Supply Chain: Why the World Can't Make Enough GLP-1 Drugs
Semaglutide is simultaneously the most commercially successful pharmaceutical launch in history and the most constrained. Novo Nordisk's Wegovy and Ozempic generated over USD 21 billion in combined revenues in 2025, with demand that consistently outstrips the company's ability to supply — not because of regulatory constraints, not because of price, but because the physical production infrastructure for injectable GLP-1 drugs does not exist at the scale that 170 million potential patients globally would require. The shortage is not temporary. It is the predictable outcome of a pharmaceutical supply chain designed around historical demand curves confronting a demand signal that is structurally larger than any previous drug class has generated. Understanding how GLP-1 drugs are made, where the bottlenecks are concentrated, and who is investing to resolve them is essential context for anyone trying to understand where this market is heading.
The Manufacturing Process That Creates the Bottleneck
GLP-1 receptor agonists like semaglutide are peptide drugs — synthetic amino acid chains produced through a combination of chemical synthesis and biological fermentation that is fundamentally different from the small-molecule chemistry underlying most pharmaceutical mass production. Peptide synthesis requires solid-phase peptide synthesis reactors operating in highly controlled cleanroom environments, specialised chromatography equipment for purification, and cold chain handling throughout the supply chain from active pharmaceutical ingredient to patient-administered device. The reaction yields at each purification stage are low by small-molecule standards — a significant proportion of the peptide produced at each step fails quality specifications and is discarded. Scaling peptide API production is not primarily a financial problem: it requires building specialised manufacturing facilities, installing custom equipment with 12–18 month lead times, validating processes to regulatory standards that typically take 2–3 years from facility construction to commercial output, and training workforces in highly specialised handling procedures that have no analogue in standard pharmaceutical manufacturing.
The fill-finish step — filling the purified semaglutide API into the prefilled injection pens that patients use — creates a second bottleneck. Autoinjector devices for GLP-1 drugs are precision medical devices requiring glass syringes, polymer pen components, and sterile fill equipment that are manufactured by a small number of specialist suppliers globally. Novo Nordisk's FlexPen and FlexTouch injection systems use glass cartridges from Schott and Gerresheimer, polymer components from specialised medical device suppliers, and are assembled on automated lines that cannot be replicated quickly. Eli Lilly faces identical constraints for Zepbound's Kwikpen device. The global medical glass supply — a mature industrial category that was never expected to face demand at GLP-1 scale — has been operating at capacity, with lead times for new manufacturing capacity of 18–30 months.
Where the Investment Is Going
Novo Nordisk has committed over USD 6 billion to manufacturing capacity expansion through 2026, including a USD 2 billion investment in its Kalundborg, Denmark API facility — the world's largest insulin and GLP-1 production complex — and investments in fill-finish capacity in Chartres, France and a new US-based facility in Clayton, North Carolina. Eli Lilly's USD 9 billion manufacturing expansion programme, announced across 2023–2025, includes new injectable drug manufacturing facilities in Indiana, North Carolina, and Germany. Contract development and manufacturing organisations — Lonza, Samsung Biologics, WuXi Biologics — are expanding peptide API manufacturing capacity to serve the GLP-1 market, with Lonza committing CHF 400 million to peptide synthesis capacity in Visp, Switzerland.
The component supply chain is also mobilising. Schott has announced EUR 1 billion in glass pharmaceutical packaging capacity expansion targeting injectable drug demand. Gerresheimer is expanding prefillable syringe production. West Pharmaceutical Services — the primary supplier of rubber closures for injectable drug vials and cartridges — has added manufacturing lines specifically in response to GLP-1 demand. The collective supply chain investment is substantial, but the regulatory validation timelines mean that the majority of new capacity will not be commercially available until 2027–2028, creating a sustained period of constrained supply that will influence pricing, access, and competitive dynamics through the end of the decade.
The Compounding Market Structure That Shortage Creates
GLP-1 drug shortages have produced a compounding pharmaceutical grey market that is both commercially significant and regulatorily contested. The FDA's shortage designation for semaglutide, which allows compounding pharmacies to legally produce and sell semaglutide formulations outside the branded product supply chain, created a USD 1+ billion compounding market by 2025. Companies including Hims & Hers, Ro, and dozens of compounding pharmacy operations sold semaglutide injections at prices 20–40% below branded Wegovy and Ozempic, sourcing bulk semaglutide API from suppliers whose quality and supply chain provenance varied significantly. The FDA's decision in February 2026 to end the shortage designation for tirzepatide — effectively shutting down compounding of Eli Lilly's drug — and the subsequent legal battles over semaglutide's status, have made compounding policy one of the most commercially significant regulatory questions in the pharmaceutical sector. Novo Nordisk and Eli Lilly are jointly fighting compounding at every regulatory and legal level; the compounding pharmacy industry is fighting back with equal intensity, and the outcome will determine the structure of a multi-billion-dollar market segment.
The Oral Formulation Race That Changes the Supply Chain
The most consequential supply chain development in GLP-1 drugs is not injectable capacity expansion — it is the race to develop oral formulations that eliminate the fill-finish and cold chain constraints entirely. Oral semaglutide (Rybelsus) has been approved at low doses for diabetes management since 2019, but higher-dose oral formulations for obesity are in Phase 3 trials. Pfizer's danuglipron, Roche's CT-388, Structure Therapeutics' GSBR-1290, and Novo Nordisk's next-generation oral semaglutide candidates are all targeting the oral obesity market. An effective oral GLP-1 drug can be manufactured using standard tablet or capsule production infrastructure, distributed through normal pharmaceutical cold chains, and dispensed through any pharmacy — eliminating the autoinjector device supply chain, the specialised glass packaging, and the cold chain logistics that currently constrain access and drive up cost. The oral formulation race is not just a patient convenience story; it is a supply chain architecture story, and the company that achieves bioavailability and efficacy comparable to injectable semaglutide in oral form will be able to scale distribution faster than any injectable programme can replicate.
What This Means for the Long-Term Market Structure
The GLP-1 supply chain constraint is temporary in the sense that it will eventually be resolved — either through capacity expansion, oral formulation, biosimilar entry (semaglutide patents expire from 2032), or some combination of all three. The constraint is permanent in the sense that it has defined the competitive dynamics, access patterns, and pricing structure of one of the largest pharmaceutical markets in history during its most critical formative period. The companies that have successfully navigated the shortage — securing manufacturing capacity, building patient relationships, establishing clinical evidence packages — will have structural advantages in the post-shortage market that may prove more durable than the patents that formally protect their products. The supply chain lesson from the GLP-1 shortage is the one pharmaceutical executives should have learned from COVID-19 vaccine manufacturing but evidently did not fully internalise: in a demand surge of this magnitude, manufacturing capacity is competitive advantage, and the companies that treated manufacturing as a cost function rather than a strategic asset will spend years catching up to those that treated it as a core capability.